Cargando…
Can targeted metabolomics predict depression recovery? Results from the CO-MED trial
Metabolomics is a developing and promising tool for exploring molecular pathways underlying symptoms of depression and predicting depression recovery. The AbsoluteIDQ™ p180 kit was used to investigate whether plasma metabolites (sphingomyelins, lysophosphatidylcholines, phosphatidylcholines, and acy...
Autores principales: | Czysz, Andrew H., South, Charles, Gadad, Bharathi S., Arning, Erland, Soyombo, Abigail, Bottiglieri, Teodoro, Trivedi, Madhukar H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341111/ https://www.ncbi.nlm.nih.gov/pubmed/30664617 http://dx.doi.org/10.1038/s41398-018-0349-6 |
Ejemplares similares
-
Fibroblast growth factor 21 (FGF21) is increased in MDD and interacts with body mass index (BMI) to affect depression trajectory
por: Mason, Brittany L., et al.
Publicado: (2022) -
Higher S100B Levels Predict Persistently Elevated Anhedonia with Escitalopram Monotherapy Versus Antidepressant Combinations: Findings from CO-MED Trial
por: Jha, Manish K., et al.
Publicado: (2019) -
Metabolomic Profiling of Adults with Congenital Heart Disease
por: Cedars, Ari, et al.
Publicado: (2021) -
Altered Brain Metabolome Is Associated with Memory Impairment in the rTg4510 Mouse Model of Tauopathy
por: Tondo, Mireia, et al.
Publicado: (2020) -
Platelet-Derived Growth Factor as an Antidepressant Treatment Selection
Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI
Combination
por: Jha, Manish K, et al.
Publicado: (2017)